Serplulimab Clinical Trials (2026): 106 Studies for Immunotherapy & Cervical Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
106 Serplulimab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 79 indications (including Immunotherapy & Cervical Cancer) and 10,884 total planned enrollment. 6 Phase 3 Serplulimab trials and 75 Phase 2, 2 Phase 4 are listed. 73 Serplulimab clinical trials are actively recruiting. Most recent activity: NCT06850103 (Dec 2032).
Serplulimab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | not yet recruiting | unknown | Total |
|---|---|---|---|---|---|---|
| P1 | 3 | 3 | ||||
| P1/P2 | 1 | 3 | 3 | 7 | ||
| P2 | 33 | 10 | 1 | 18 | 13 | 75 |
| P2/P3 | 1 | 1 | 2 | 4 | ||
| P3 | 2 | 1 | 3 | 6 | ||
| P4 | 2 | 2 | ||||
| N/A | 2 | 3 | 4 | 9 |
Recruiting Serplulimab clinical trials (73)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06850103 | SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases | P2 | Colorectal Carcinoma | 51 | Apr 2025 |
| NCT07381400 | Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study) | P2 | Rectal Cancer | 128 | Feb 2026 |
| NCT07177443 | Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma | P3 | Locally Advanced Nasopharyngeal Carcinoma | 456 | Sep 2025 |
| NCT07283692 | Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) | P2 | Triple Negative Breast Cancer | 46 | Mar 2026 |
| NCT07527520 | Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial | P2 | Rectal Cancer | 165 | Jun 2026 |
| NCT07466303 | Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer | P2 | Breast Cancer | 84 | Mar 2026 |
| NCT07318883 | A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer | P2/P3 | Squamous NSCLC | 720 | Mar 2026 |
| NCT07141771 | An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing | P1/P2 | SCLC, Extensive Stage | 100 | Dec 2025 |
| NCT07347951 | A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer | P2 | Locally Advanced Rectal Cancer (LARC) | 30 | Dec 2025 |
| NCT06781281 | NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer. | — | Breast Cancer Invasive | 709 | Dec 2024 |
| NCT07155122 | Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the Esophageal | P2 | Small-Cell Carcinoma of the Esophageal | 15 | Sep 2025 |
| NCT07134101 | SMARTi-RC01Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01) | P2 | Colorectal Cancer (Diagnosis) | 138 | Sep 2025 |
| NCT06580665 | Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer | N/A | Non-small Cell Lung Cancer | 134 | Sep 2024 |
| NCT07403435 | Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC | P2 | Esophageal Squamous Cell Carcinoma (ESCC) | 22 | Feb 2026 |
| NCT06860529 | Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer | P2 | HR+/HER2- Breast Cancer | 357 | Apr 2025 |
| NCT07398937 | ECTOP-1036Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC | P2 | Resectable Stage II-IIIa Squamous NSCLC | 116 | Feb 2026 |
| NCT06692491 | SPRINGStudy of Precision Treatment for Rare Tumours in China Guided by PDO and NGS | P2 | Rare Tumour | 200 | Jan 2025 |
| NCT06280495 | Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients | P2/P3 | Colorectal Cancer | 156 | Feb 2024 |
| NCT07604909 | A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy | P2 | Colorectal Cancer | 40 | May 2026 |
| NCT07506057 | SHIELDTrastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy | P2 | Urothelial Carcinoma | 20 | Jul 2025 |
| NCT07235930 | Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer | P3 | Non-Resectable Pancreas Carcinoma | 292 | Nov 2025 |
| NCT05872685 | FOCUS-05Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05) | P2 | Adenocarcinoma of the Stomach | 314 | Dec 2023 |
| NCT05975749 | Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer | P2 | Gastric Cancer | 114 | Jan 2023 |
| NCT07543848 | A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer | P2 | Rectal Neoplasms | 20 | May 2026 |
| NCT07231445 | Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer | P1 | Small Cell Lung Cancer | 100 | Apr 2026 |
| NCT07418866 | FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung Cancer | P2 | NSCLC (Advanced Non-small Cell Lung Cancer) | 70 | Feb 2026 |
| NCT07172412 | Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer | P2 | Extensive Stage Lung Small Cell Cancer | 165 | Nov 2025 |
| NCT07277842 | PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer | P3 | Locally Advanced Low Rectal Adenocarcinoma | 382 | Dec 2025 |
| NCT07150949 | SERRACLong-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC) | P2 | Locally Advanced Rectal Cancer | 138 | Aug 2025 |
| NCT07358585 | A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer | P1/P2 | Colon Cancer Adenocarcinoma | 126 | Jan 2026 |
| NCT07336953 | A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2) | P3 | PDAC - Pancreatic Ductal Adenocarcinoma | 198 | Feb 2026 |
| NCT05742425 | Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases | P2 | Unresectable Colon Cancer Peritoneal Metastases | 30 | Mar 2023 |
| NCT07020247 | Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study | P3 | Locally Advanced Rectal Cancer (LARC) | 184 | Nov 2024 |
| NCT07391826 | Megestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX | P2 | Stage III Gastric Cancer | 48 | Feb 2026 |
| NCT06461910 | Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma | P2 | Gastric Cancer | 30 | Jun 2024 |
| NCT06295926 | Serplulimab Combined With CCRT for LS-SCLC. | P2 | Small Cell Lung Cancer | 96 | Apr 2024 |
| NCT06716619 | A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors | P1 | Tumor Associated Lymph Node T Cell | 32 | Feb 2025 |
| NCT07583511 | Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study | P2 | Small-cell Lung Cancer | 90 | Feb 2024 |
| NCT06354218 | Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age | P2 | Esophageal Carcinoma | 50 | Dec 2023 |
| NCT07340489 | Serplulimab for Locally Advanced Cervical Cancer | P2 | Cervical Cancer | 216 | Dec 2025 |
| NCT07134218 | Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer | P2/P3 | Rectal Cancer | 180 | Oct 2025 |
| NCT07175389 | JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure | P1/P2 | Refractory Pancreatic Ductal Adenocarcinoma | 10 | Oct 2025 |
| NCT06848699 | A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors | P1/P2 | Solid Tumor Cancer | 105 | Feb 2025 |
| NCT06554535 | Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer | P2 | Extensive-Stage Small Cell Lung Cancer | 43 | Oct 2024 |
| NCT07064876 | Serplulimab Combined With Cryoablation for Early-Stage Non-Small Cell Lung Cancer | P2 | Early Lung Cancer | 25 | Oct 2025 |
| NCT06099951 | Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy | P2 | Colorectal Cancer | 53 | Nov 2023 |
| NCT05954429 | A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study | P2 | Colorectal Cancer | 50 | Jul 2023 |
| NCT06531291 | Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation | P2 | ESCC | 80 | Aug 2024 |
| NCT06521866 | Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer | P2 | Advanced Colorectal Carcinoma | 208 | Mar 2025 |
| NCT06128252 | Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer | N/A | Gastric Cancer | 96 | Sep 2024 |
| NCT06462105 | Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer | N/A | Small Cell Lung Cancer | 60 | Jul 2024 |
| NCT07596121 | Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50% | P2 | NSCLC (Non-small Cell Lung Cancer) | 60 | May 2026 |
| NCT06388135 | Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma | P4 | Esophageal Squamous Cell Carcinoma | 80 | May 2024 |
| NCT05766800 | Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer | P2 | Locally Advanced | 100 | Mar 2023 |
| NCT07446465 | FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer | P4 | Colorectal Cancer (Locally Advanced or Metastatic) | 42 | Mar 2026 |
| NCT06156332 | A Study of Surufatinib Combined With Serplulimab in the Treatment of Advanced Solid Tumors With Neuroendocrine Differentiation That Failed Standard Therapy | N/A | Advanced Solid Tumors With Neuroendocrine Differentiation | 39 | Jan 2024 |
| NCT06727617 | Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors | P2 | Cervical Cancers | 134 | Nov 2024 |
| NCT06497530 | Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC | P2 | Extensive-Stage Small Cell Lung Cancer | 30 | Dec 2024 |
| NCT06542588 | Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC | P2 | Rectal Cancer | 29 | Jul 2024 |
| NCT06439550 | Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC | P2 | HER2-positive Gastric Cancer | 42 | Jul 2024 |
| NCT06433869 | The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites | P2 | Malignant Ascites | 60 | Dec 2023 |
| NCT05957510 | Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment | P2 | Small-cell Lung Cancer | 66 | Jul 2023 |
| NCT05731726 | Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer | P2 | pMMR | 50 | Feb 2023 |
| NCT06601309 | ESCCBiomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC | P2 | Esophageal Squamous Cell Carcinoma | 90 | Jul 2024 |
| NCT07269782 | A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC | P2 | Non Small Cell Lung Cancer | 60 | Jan 2026 |
| NCT05988372 | SAGESurufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE) | P2 | Locally Advanced Pancreatic Cancer | 50 | Oct 2023 |
| NCT06576921 | Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction | P2 | Stomach Neoplasms | 116 | Nov 2024 |
| NCT06491355 | First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer | P2 | Efficacy, Self | 72 | Jul 2024 |
| NCT06911606 | LS-SCLCStudy of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC) | P2 | SCLC, Limited Stage | 45 | May 2024 |
| NCT06302062 | TAL-TPhase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors | P1 | Advanced Solid Tumor | 23 | Jun 2023 |
| NCT06368141 | NeoCHICNeoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer | P2 | Colon Cancer | 56 | May 2024 |
| NCT06455072 | Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer | P2 | Cervical Cancer | 37 | Feb 2023 |
| NCT06496789 | Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer | P2 | Gastric Adenocarcinoma | 35 | May 2023 |
Serplulimab clinical trials by indication
Colorectal Cancer (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06280495 | — | P2/P3 | recruiting | Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients |
| NCT07604909 | — | P2 | recruiting | A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy |
| NCT06099951 | — | P2 | not yet recruiting | Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy |
| NCT05954429 | — | P2 | recruiting | A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study |
| NCT05894837 | — | P2 | unknown | Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases |
Cervical Cancer (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06419673 | — | P2 | active not recruiting | Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer |
| NCT07340489 | — | P2 | recruiting | Serplulimab for Locally Advanced Cervical Cancer |
| NCT05883670 | — | N/A | unknown | Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer |
| NCT05444374 | — | P2 | unknown | A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer |
| NCT06455072 | — | P2 | recruiting | Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer |
Rectal Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07381400 | — | P2 | not yet recruiting | Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study) |
| NCT07527520 | — | P2 | not yet recruiting | Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial |
| NCT07134218 | — | P2/P3 | not yet recruiting | Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer |
| NCT06542588 | — | P2 | recruiting | Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC |
Small Cell Lung Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07231445 | — | P1 | recruiting | Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer |
| NCT06295926 | — | P2 | recruiting | Serplulimab Combined With CCRT for LS-SCLC. |
| NCT06462105 | — | N/A | not yet recruiting | Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer |
| NCT05882630 | — | P1/P2 | unknown | Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer |
Gastric Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05975749 | — | P2 | recruiting | Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer |
| NCT06461910 | — | P2 | recruiting | Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma |
| NCT06128252 | — | N/A | recruiting | Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer |
Non-small Cell Lung Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06580665 | — | N/A | not yet recruiting | Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer |
| NCT05775796 | ECTOP-1013 | P2 | completed | Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013) |
| NCT06195683 | NSCLC | P2 | unknown | Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study. |
Esophageal Squamous Cell Carcinoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05659251 | — | P2 | active not recruiting | Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma |
| NCT06388135 | — | P4 | not yet recruiting | Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma |
| NCT06601309 | ESCC | P2 | recruiting | Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC |
Breast Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07466303 | — | P2 | not yet recruiting | Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer |
| NCT06394661 | — | P2 | active not recruiting | Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer |
Locally Advanced Rectal Cancer (LARC) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07347951 | — | P2 | recruiting | A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer |
| NCT07020247 | — | P3 | recruiting | Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study |
Extensive Stage Lung Small Cell Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07172412 | — | P2 | not yet recruiting | Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer |
| NCT06350162 | — | P2 | unknown | Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC |
Non-Resectable Pancreas Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07235930 | — | P3 | recruiting | Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer |
| NCT06393166 | — | P2 | unknown | Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer |
Extensive-Stage Small Cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06554535 | — | P2 | not yet recruiting | Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer |
| NCT06497530 | — | P2 | recruiting | Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC |
Small-cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07583511 | — | P2 | recruiting | Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study |
| NCT05957510 | — | P2 | recruiting | Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment |
Malignant Ascites (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06433869 | — | P2 | recruiting | The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites |
| NCT05501340 | — | P1/P2 | unknown | PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites |
NSCLC (Non-small Cell Lung Cancer) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07596121 | — | P2 | recruiting | Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50% |
Rectal Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07543848 | — | P2 | not yet recruiting | A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer |
Squamous NSCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07318883 | — | P2/P3 | not yet recruiting | A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer |
Triple Negative Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07283692 | — | P2 | recruiting | Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) |
Colorectal Cancer (Locally Advanced or Metastatic) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07446465 | — | P4 | not yet recruiting | FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer |
NSCLC (Advanced Non-small Cell Lung Cancer) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07418866 | — | P2 | not yet recruiting | FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung Cancer |
PDAC - Pancreatic Ductal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07336953 | — | P3 | not yet recruiting | A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2) |
Esophageal Squamous Cell Carcinoma (ESCC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07403435 | — | P2 | not yet recruiting | Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC |
Stage III Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07391826 | — | P2 | not yet recruiting | Megestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX |
Resectable Stage II-IIIa Squamous NSCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07398937 | ECTOP-1036 | P2 | recruiting | Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC |
Colon Cancer Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07358585 | — | P1/P2 | not yet recruiting | A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer |
Non Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07269782 | — | P2 | recruiting | A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC |
SCLC, Extensive Stage (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07141771 | — | P1/P2 | not yet recruiting | An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing |
Locally Advanced Low Rectal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07277842 | — | P3 | not yet recruiting | PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer |
Early Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07064876 | — | P2 | not yet recruiting | Serplulimab Combined With Cryoablation for Early-Stage Non-Small Cell Lung Cancer |
Refractory Pancreatic Ductal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07175389 | — | P1/P2 | not yet recruiting | JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure |
Locally Advanced Nasopharyngeal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07177443 | — | P3 | not yet recruiting | Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma |
Colorectal Cancer (Diagnosis) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07134101 | SMARTi-RC01 | P2 | not yet recruiting | Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01) |
Small-Cell Carcinoma of the Esophageal (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07155122 | — | P2 | not yet recruiting | Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the Esophageal |
Locally Advanced Rectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07150949 | SERRAC | P2 | recruiting | Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC) |
Non-Clear Cell Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07488533 | — | P2 | active not recruiting | Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma |
Urothelial Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07506057 | SHIELD | P2 | recruiting | Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy |
Colorectal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06850103 | — | P2 | recruiting | SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases |
HR+/HER2- Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06860529 | — | P2 | recruiting | Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer |
Advanced Colorectal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06521866 | — | P2 | recruiting | Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer |
Solid Tumor Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06848699 | — | P1/P2 | recruiting | A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors |
Tumor Associated Lymph Node T Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06716619 | — | P1 | recruiting | A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors |
Gastric Cancer Stage III (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07257575 | — | P2 | active not recruiting | A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma |
Rare Tumour (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06692491 | SPRING | P2 | not yet recruiting | Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS |
Breast Cancer Invasive (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06781281 | — | N/A | recruiting | NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer. |
Cervical Cancers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06727617 | — | P2 | recruiting | Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors |
Stomach Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06576921 | — | P2 | recruiting | Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction |
ESCC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06531291 | — | P2 | not yet recruiting | Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation |
HER2-positive Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06439550 | — | P2 | not yet recruiting | Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC |
Efficacy, Self (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06491355 | — | P2 | not yet recruiting | First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer |
SCLC, Limited Stage (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06911606 | LS-SCLC | P2 | recruiting | Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC) |
Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06422858 | Stars | P2 | unknown | Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma |
Colon Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06368141 | NeoCHIC | P2 | recruiting | Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer |
Metastatic Colon Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06335147 | — | N/A | unknown | PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer |
Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06364046 | — | N/A | unknown | Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC |
Advanced Solid Tumors With Neuroendocrine Differentiation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06156332 | — | N/A | not yet recruiting | A Study of Surufatinib Combined With Serplulimab in the Treatment of Advanced Solid Tumors With Neuroendocrine Differentiation That Failed Standard Therapy |
Adenocarcinoma of the Stomach (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05872685 | FOCUS-05 | P2 | recruiting | Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05) |
Esophageal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06354218 | — | P2 | recruiting | Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age |
Locally Advanced Pancreatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05988372 | SAGE | P2 | not yet recruiting | Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE) |
NSCLC Stage IV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05787613 | — | P2 | active not recruiting | A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients |
Advanced Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06302062 | TAL-T | P1 | recruiting | Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors |
Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05873790 | — | N/A | unknown | Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive Small Cell Lung Cancer: An Observational Study |
Gastric Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06496789 | — | P2 | recruiting | Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer |
NSCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05882513 | — | P2 | active not recruiting | Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer |
Non-small Cell Lung Cancer Stage II (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05807893 | SUPER BRAIN | P2/P3 | completed | Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases |
Non-Squamous Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06334757 | — | P2 | unknown | Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure |
Non-clear Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05831891 | — | P2 | active not recruiting | Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma |
Advanced Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06370065 | HCC | P2 | unknown | Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients |
Unresectable Colon Cancer Peritoneal Metastases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05742425 | — | P2 | recruiting | Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases |
Locally Advanced (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05766800 | — | P2 | recruiting | Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer |
Extensive-stage Small-cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05765825 | — | P2 | active not recruiting | Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC |
Locally Advanced Colon Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05732493 | TORCH-C | P2 | unknown | Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer(TORCH-C) |
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05585580 | — | P2 | active not recruiting | Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy |
Serplulimab,Gastric Cancer, Adjuvant Therapy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05769725 | — | P2 | unknown | A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer |
Neuroendocrine Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05747729 | — | P1/P2 | unknown | A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma. |
pMMR (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05731726 | — | P2 | recruiting | Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer |
Gastroesophageal Junction Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05918419 | SNACRT | P2 | unknown | Efficacy and Safety of Neoadjuvant Chemoradiation Plus Serplulimab in Patients With Locally Advanced Adenocarcinoma of Gastroesophageal Junction |
Lung Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05675033 | — | P2 | unknown | Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma |
Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05942573 | — | P2 | unknown | Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial |
Extensive Stage Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05468489 | — | P3 | active not recruiting | To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC |
Serplulimab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| SMARTi-RC01 | NCT07134101 | P2 | not yet recruiting | Colorectal Cancer (Diagnosis) | 138 | — |
| ECTOP-1036 | NCT07398937 | P2 | recruiting | Resectable Stage II-IIIa Squamous NSCLC | 116 | — |
| SPRING | NCT06692491 | P2 | not yet recruiting | Rare Tumour | 200 | — |
| SHIELD | NCT07506057 | P2 | recruiting | Urothelial Carcinoma | 20 | — |
| FOCUS-05 | NCT05872685 | P2 | recruiting | Adenocarcinoma of the Stomach | 314 | — |
| SERRAC | NCT07150949 | P2 | recruiting | Locally Advanced Rectal Cancer | 138 | — |
| ESCC | NCT06601309 | P2 | recruiting | Esophageal Squamous Cell Carcinoma | 90 | — |
| SAGE | NCT05988372 | P2 | not yet recruiting | Locally Advanced Pancreatic Cancer | 50 | — |
| LS-SCLC | NCT06911606 | P2 | recruiting | SCLC, Limited Stage | 45 | — |
| Stars | NCT06422858 | P2 | unknown | Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma | 37 | — |
| NeoCHIC | NCT06368141 | P2 | recruiting | Colon Cancer | 56 | — |
| ECTOP-1013 | NCT05775796 | P2 | completed | Non-small Cell Lung Cancer | 30 | PMID 42114951 |
| NSCLC | NCT06195683 | P2 | unknown | Non-small Cell Lung Cancer | 23 | — |
| HCC | NCT06370065 | P2 | unknown | Advanced Hepatocellular Carcinoma | 35 | — |
| TORCH-C | NCT05732493 | P2 | unknown | Locally Advanced Colon Cancer | 120 | PMID 38309748 |
| SNACRT | NCT05918419 | P2 | unknown | Gastroesophageal Junction Adenocarcinoma | 35 | — |
All Serplulimab trials (106)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06850103 | SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases | P2 | recruiting | 51 | First Affiliated Hospital of Zhejiang University | Apr 2025 | |
| NCT07381400 | Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study) | P2 | not yet recruiting | 128 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Feb 2026 | |
| NCT07177443 | Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma | P3 | not yet recruiting | 456 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Sep 2025 | |
| NCT07283692 | Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) | P2 | recruiting | 46 | RenJi Hospital | Mar 2026 | |
| NCT07527520 | Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial | P2 | not yet recruiting | 165 | Fudan University | Jun 2026 | |
| NCT07257575 | A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma | P2 | active not recruiting | 138 | Guangdong Provincial People's Hospital | Jan 2025 | |
| NCT07466303 | Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer | P2 | not yet recruiting | 84 | Xijing Hospital | Mar 2026 | |
| NCT07318883 | A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer | P2/P3 | not yet recruiting | 720 | Shanghai Henlius Biotech | Mar 2026 | |
| NCT07141771 | An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing | P1/P2 | not yet recruiting | 100 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Dec 2025 | |
| NCT05882513 | Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer | P2 | active not recruiting | 36 | Second Affiliated Hospital, School of Medicine, Zhejiang University | May 2023 | |
| NCT07347951 | A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer | P2 | recruiting | 30 | First Affiliated Hospital of Wenzhou Medical University | Dec 2025 | |
| NCT06781281 | NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer. | — | recruiting | 709 | Henan Cancer Hospital | Dec 2024 | |
| NCT07155122 | Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the Esophageal | P2 | not yet recruiting | 15 | Fujian Cancer Hospital | Sep 2025 | |
| NCT07134101 | SMARTi-RC01 | Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01) | P2 | not yet recruiting | 138 | The First Affiliated Hospital with Nanjing Medical University | Sep 2025 |
| NCT06580665 | Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer | N/A | not yet recruiting | 134 | Shanghai Chest Hospital | Sep 2024 | |
| NCT07403435 | Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC | P2 | not yet recruiting | 22 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Feb 2026 | |
| NCT06860529 | Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer | P2 | recruiting | 357 | Henan Cancer Hospital | Apr 2025 | |
| NCT07398937 | ECTOP-1036 | Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC | P2 | recruiting | 116 | Fudan University | Feb 2026 |
| NCT06692491 | SPRING | Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS | P2 | not yet recruiting | 200 | Peking University Shenzhen Hospital | Jan 2025 |
| NCT06280495 | Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients | P2/P3 | recruiting | 156 | Sun Yat-sen University | Feb 2024 | |
| NCT05659251 | Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma | P2 | active not recruiting | 48 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Dec 2022 | |
| NCT07604909 | A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy | P2 | recruiting | 40 | Fudan University | May 2026 | |
| NCT07506057 | SHIELD | Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy | P2 | recruiting | 20 | Xiujuan Qu | Jul 2025 |
| NCT07235930 | Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer | P3 | recruiting | 292 | Zhejiang Cancer Hospital | Nov 2025 | |
| NCT05872685 | FOCUS-05 | Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05) | P2 | recruiting | 314 | Yu jiren | Dec 2023 |
| NCT05975749 | Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer | P2 | recruiting | 114 | Fudan University | Jan 2023 | |
| NCT07543848 | A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer | P2 | not yet recruiting | 20 | Chongqing University Cancer Hospital | May 2026 | |
| NCT07231445 | Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer | P1 | recruiting | 100 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Apr 2026 | |
| NCT07418866 | FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung Cancer | P2 | not yet recruiting | 70 | Fudan University | Feb 2026 | |
| NCT07172412 | Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer | P2 | not yet recruiting | 165 | Tianjin Medical University Cancer Institute and Hospital | Nov 2025 | |
| NCT07488533 | Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma | P2 | active not recruiting | 40 | Sun Yat-sen University | Aug 2025 | |
| NCT06394661 | Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer | P2 | active not recruiting | 109 | Henan Cancer Hospital | Apr 2024 | |
| NCT07277842 | PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer | P3 | not yet recruiting | 382 | Sun Yat-sen University | Dec 2025 | |
| NCT07150949 | SERRAC | Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC) | P2 | recruiting | 138 | Fudan University | Aug 2025 |
| NCT07358585 | A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer | P1/P2 | not yet recruiting | 126 | Shanghai Henlius Biotech | Jan 2026 | |
| NCT07336953 | A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2) | P3 | not yet recruiting | 198 | West China Hospital | Feb 2026 | |
| NCT06419673 | Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer | P2 | active not recruiting | 240 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | May 2024 | |
| NCT05742425 | Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases | P2 | recruiting | 30 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Mar 2023 | |
| NCT07020247 | Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study | P3 | recruiting | 184 | West China Hospital | Nov 2024 | |
| NCT07391826 | Megestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX | P2 | not yet recruiting | 48 | The First Affiliated Hospital with Nanjing Medical University | Feb 2026 | |
| NCT06461910 | Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma | P2 | recruiting | 30 | Zekuan Xu | Jun 2024 | |
| NCT06295926 | Serplulimab Combined With CCRT for LS-SCLC. | P2 | recruiting | 96 | Peking Union Medical College Hospital | Apr 2024 | |
| NCT05468489 | To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC | P3 | active not recruiting | 200 | Shanghai Henlius Biotech | Nov 2022 | |
| NCT06716619 | A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors | P1 | recruiting | 32 | Guangzhou FineImmune Biotechnology Co., LTD. | Feb 2025 | |
| NCT07583511 | Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study | P2 | recruiting | 90 | Sun Yat-sen University | Feb 2024 | |
| NCT06354218 | Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age | P2 | recruiting | 50 | The First Affiliated Hospital with Nanjing Medical University | Dec 2023 | |
| NCT07340489 | Serplulimab for Locally Advanced Cervical Cancer | P2 | recruiting | 216 | Tianjin Medical University Cancer Institute and Hospital | Dec 2025 | |
| NCT07134218 | Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer | P2/P3 | not yet recruiting | 180 | Changhai Hospital | Oct 2025 | |
| NCT07175389 | JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure | P1/P2 | not yet recruiting | 10 | West China Hospital | Oct 2025 | |
| NCT06848699 | A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors | P1/P2 | recruiting | 105 | Shanghai Henlius Biotech | Feb 2025 | |
| NCT06554535 | Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer | P2 | not yet recruiting | 43 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Oct 2024 | |
| NCT07064876 | Serplulimab Combined With Cryoablation for Early-Stage Non-Small Cell Lung Cancer | P2 | not yet recruiting | 25 | Xi Junjie | Oct 2025 | |
| NCT06099951 | Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy | P2 | not yet recruiting | 53 | Sun Yat-sen University | Nov 2023 | |
| NCT05954429 | A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study | P2 | recruiting | 50 | Fudan University | Jul 2023 | |
| NCT06531291 | Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation | P2 | not yet recruiting | 80 | RenJi Hospital | Aug 2024 | |
| NCT06521866 | Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer | P2 | recruiting | 208 | Fudan University | Mar 2025 | |
| NCT05787613 | A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients | P2 | active not recruiting | 132 | Shanghai Henlius Biotech | Jul 2023 | |
| NCT06128252 | Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer | N/A | recruiting | 96 | Tang-Du Hospital | Sep 2024 | |
| NCT06462105 | Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer | N/A | not yet recruiting | 60 | Zhou Chengzhi | Jul 2024 | |
| NCT07596121 | Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50% | P2 | recruiting | 60 | Tang-Du Hospital | May 2026 | |
| NCT06388135 | Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma | P4 | not yet recruiting | 80 | Yang Jianjun, PhD | May 2024 | |
| NCT05766800 | Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer | P2 | recruiting | 100 | Shanghai Pulmonary Hospital, Shanghai, China | Mar 2023 | |
| NCT07446465 | FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer | P4 | not yet recruiting | 42 | Ye Xu | Mar 2026 | |
| NCT06156332 | A Study of Surufatinib Combined With Serplulimab in the Treatment of Advanced Solid Tumors With Neuroendocrine Differentiation That Failed Standard Therapy | N/A | not yet recruiting | 39 | Shanghai Changzheng Hospital | Jan 2024 | |
| NCT06727617 | Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors | P2 | recruiting | 134 | Tianjin Medical University Cancer Institute and Hospital | Nov 2024 | |
| NCT06497530 | Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC | P2 | recruiting | 30 | Guangzhou Institute of Respiratory Disease | Dec 2024 | |
| NCT06542588 | Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC | P2 | recruiting | 29 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Jul 2024 | |
| NCT06439550 | Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC | P2 | not yet recruiting | 42 | The First Affiliated Hospital of Zhengzhou University | Jul 2024 | |
| NCT06433869 | The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites | P2 | recruiting | 60 | Sun Yat-sen University | Dec 2023 | |
| NCT05957510 | Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment | P2 | recruiting | 66 | Guangdong Association of Clinical Trials | Jul 2023 | |
| NCT05831891 | Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma | P2 | active not recruiting | 39 | RenJi Hospital | May 2023 | |
| NCT05765825 | Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC | P2 | active not recruiting | 61 | Sichuan University | Mar 2023 | |
| NCT05731726 | Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer | P2 | recruiting | 50 | Zhejiang University | Feb 2023 | |
| NCT06601309 | ESCC | Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC | P2 | recruiting | 90 | Fujian Medical University Union Hospital | Jul 2024 |
| NCT07269782 | A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC | P2 | recruiting | 60 | Shanghai Henlius Biotech | Jan 2026 | |
| NCT05585580 | Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy | P2 | active not recruiting | 59 | Qilu Hospital of Shandong University | Mar 2023 | |
| NCT05988372 | SAGE | Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE) | P2 | not yet recruiting | 50 | Sun Yat-sen University | Oct 2023 |
| NCT06576921 | Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction | P2 | recruiting | 116 | Xijing Hospital | Nov 2024 | |
| NCT06491355 | First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer | P2 | not yet recruiting | 72 | Sir Run Run Shaw Hospital | Jul 2024 | |
| NCT06911606 | LS-SCLC | Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC) | P2 | recruiting | 45 | Guangdong Provincial People's Hospital | May 2024 |
| NCT06302062 | TAL-T | Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors | P1 | recruiting | 23 | Guangzhou FineImmune Biotechnology Co., LTD. | Jun 2023 |
| NCT05882630 | Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer | P1/P2 | unknown | 39 | Fujian Cancer Hospital | Jun 2023 | |
| NCT06422858 | Stars | Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma | P2 | unknown | 37 | Zhejiang Cancer Hospital | May 2024 |
| NCT06368141 | NeoCHIC | Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer | P2 | recruiting | 56 | Ruijin Hospital | May 2024 |
| NCT05769725 | A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer | P2 | unknown | 70 | RenJi Hospital | Mar 2023 | |
| NCT05747729 | A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma. | P1/P2 | unknown | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Feb 2023 | |
| NCT06335147 | PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer | N/A | unknown | 23 | Henan Cancer Hospital | Apr 2024 | |
| NCT06364046 | Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC | N/A | unknown | 56 | The Central Hospital of Lishui City | Apr 2024 | |
| NCT06350162 | Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC | P2 | unknown | 100 | Zhejiang Cancer Hospital | Oct 2023 | |
| NCT06393166 | Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer | P2 | unknown | 37 | Zhejiang Cancer Hospital | May 2023 | |
| NCT05883670 | Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer | — | unknown | 118 | Shandong University | Mar 2023 | |
| NCT05444374 | A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer | P2 | unknown | 48 | Sichuan Cancer Hospital and Research Institute | Oct 2022 | |
| NCT05775796 | ECTOP-1013 | Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013) | P2 | completed | 30 | Fudan University | Mar 2023 |
| NCT06334757 | Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure | P2 | unknown | 46 | Henan Cancer Hospital | May 2023 | |
| NCT06195683 | NSCLC | Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study. | P2 | unknown | 23 | Zhejiang Cancer Hospital | Dec 2023 |
| NCT05894837 | Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases | P2 | unknown | 30 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Jun 2023 | |
| NCT06455072 | Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer | P2 | recruiting | 37 | Fujian Cancer Hospital | Feb 2023 | |
| NCT05873790 | Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive Small Cell Lung Cancer: An Observational Study | — | unknown | 30 | The First Hospital of Jilin University | Jun 2023 | |
| NCT06496789 | Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer | P2 | recruiting | 35 | Tianjin Medical University Cancer Institute and Hospital | May 2023 | |
| NCT06370065 | HCC | Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients | P2 | unknown | 35 | Tianjin Medical University Cancer Institute and Hospital | Apr 2023 |
| NCT05732493 | TORCH-C | Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer(TORCH-C) | P2 | unknown | 120 | Fudan University | Mar 2023 |
| NCT05942573 | Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial | P2 | unknown | 107 | Tianjin Medical University Cancer Institute and Hospital | Dec 2022 | |
| NCT05918419 | SNACRT | Efficacy and Safety of Neoadjuvant Chemoradiation Plus Serplulimab in Patients With Locally Advanced Adenocarcinoma of Gastroesophageal Junction | P2 | unknown | 35 | Peking Union Medical College Hospital | Feb 2023 |
| NCT05501340 | PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites | P1/P2 | unknown | 40 | Second Affiliated Hospital of Soochow University | Sep 2022 | |
| NCT05807893 | SUPER BRAIN | Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases | P2/P3 | completed | 40 | Sun Yat-sen University | May 2023 |
| NCT05675033 | Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma | P2 | unknown | 50 | Fujian Cancer Hospital | Jan 2023 |
Serplulimab clinical trials: frequently asked questions
- How many Serplulimab clinical trials are there?
- 106 Serplulimab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 42 are actively recruiting participants. 2 are marked completed.
- Are Serplulimab clinical trials recruiting in 2026?
- Yes — 42 Serplulimab trials are actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
- What conditions is Serplulimab being studied for?
- Serplulimab is being studied for Immunotherapy, Cervical Cancer, Small Cell Lung Cancer, Colorectal Cancer, Neoadjuvant Therapy and 115 more. The trials are grouped by indication on this page.
- What phase is Serplulimab in?
- Serplulimab clinical trials span 2 Phase 4, 6 Phase 3, 75 Phase 2, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Serplulimab clinical trials?
- The lead sponsor across the most Serplulimab trials is Fudan University, with 49 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Serplulimabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: